Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) have received a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $8.33.
A number of equities research analysts have weighed in on the stock. ValuEngine upgraded shares of Tonix Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Dawson James restated a “buy” rating and issued a $9.00 price objective on shares of Tonix Pharmaceuticals in a research note on Wednesday, August 23rd. Roth Capital upgraded Tonix Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Friday, August 18th. They noted that the move was a valuation call. Finally, Drexel Hamilton initiated coverage on Tonix Pharmaceuticals in a research note on Tuesday, August 22nd. They issued a “buy” rating for the company.
A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. B. Riley Financial Inc. purchased a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 378,138 shares of the company’s stock, valued at approximately $1,637,000. B. Riley Financial Inc. owned approximately 5.05% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 17.51% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/01/tonix-pharmaceuticals-holding-corp-tnxp-receives-average-rating-of-buy-from-analysts.html.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.